Company profile: Vaxcyte
1.1 - Company Overview
Company description
- Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
Products and services
- XpressCF™: A cell-free protein synthesis platform that produces vaccine components using precise, site-specific conjugation to enhance immunogenicity
- VAX-24: An FDA Breakthrough Therapy-designated, 24-valent pneumococcal conjugate vaccine engineered to prevent invasive pneumococcal disease in adults by covering 24 serotypes
- VAX-31: A high-valency, 31-valent pneumococcal conjugate vaccine candidate in development aimed at covering a broader spectrum of pneumococcal disease
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Vaxcyte
Fast Track Diagnostics
HQ: Malta
Website
- Description: Provider of infectious disease diagnostics tests and detection kits using syndromic multiplex real time PCR to distinguish viral, bacterial, or other infections in a single test; a global supplier specializing in the design, development and manufacture of FTD assays.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fast Track Diagnostics company profile →
Emergent BioSolutions
HQ: United States
Website
- Description: Provider of medical countermeasures for biological and chemical threats, developing, manufacturing, and delivering products including NARCAN® Nasal Spray to rapidly reverse opioid overdose; BioThrax® and CYFENDUS™ anthrax vaccines; ACAM2000® smallpox vaccine; TEMBEXA® antiviral for smallpox; and EbangaTM therapeutic antibody for Ebola virus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Emergent BioSolutions company profile →
iosBio
HQ: United Kingdom
Website
- Description: Provider of thermally stable oral vaccine platforms and services, offering vaccine manufacturing, distribution, and delivery. Its OraPro technology uses viral vectors to deliver capsule-based vaccines to the GI tract, enabling mucosal and systemic immunity without cold-chain storage. Products include OraPro and OraPro-Covid-19, an at-home oral vaccine targeting S and N proteins.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iosBio company profile →
Mymetics
HQ: Switzerland
Website
- Description: Provider of virosome-based vaccine R&D and immunotherapies, focused on next-generation preventative vaccines for infectious diseases. Pipeline includes HIV-1/AIDS, intranasal influenza, malaria, herpes simplex virus and RSV, plus candidates for Covid-19 and COP allergy immunotherapy, and research collaborations in cancer immunotherapy. Swiss-based with a research lab in the Netherlands.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Mymetics company profile →
Aquapharm
HQ: United Kingdom
Website
- Description: Provider of drug discovery products based on the chemical diversity of marine micro-organisms, including novel pharmaceutical compounds and antibiotics for Gram negative and Gram positive infections, bio-manufactured nutraceuticals, personal care ingredients, and industrial biocatalysts. Maintains a proprietary library of over 7,000 marine micro-organisms and uses SeaRch™ technology to screen and induce production of biologically active compounds.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aquapharm company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Vaxcyte
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Vaxcyte
2.2 - Growth funds investing in similar companies to Vaxcyte
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Vaxcyte
4.2 - Public trading comparable groups for Vaxcyte
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →